hospira tranexamic acid injection tranexamic acid 1000 mg in 10 ml ampoule
pfizer australia pty ltd - tranexamic acid -
hospira tranexamic acid injection tranexamic acid 500 mg in 5 ml ampoule
pfizer australia pty ltd - tranexamic acid -
methotrexate (hospira)
hospira nz ltd - methotrexate 10 mg/ml; - solution for injection - 20 mg/2ml - active: methotrexate 10 mg/ml excipient: sodium chloride sodium hydroxide water for injection
hospira ceftazidime powder for injection ceftazidime (as pentahydrate) 2 g powder for injection vial
pfizer australia pty ltd - ceftazidime pentahydrate -
hospira ceftazidime powder for injection ceftazidime (as pentahydrate) 1 g powder for injection vial
pfizer australia pty ltd - ceftazidime pentahydrate -
hospira cefazolin sodium for injection cefazolin (as sodium) 1 g powder for injection vial
pfizer australia pty ltd - cefazolin sodium -
hospira cefoxitin sodium powder for injection cefoxitin (as sodium) 1 g powder for injection vial
pfizer australia pty ltd - cefoxitin sodium -
hospira ceftriaxone sodium powder for injection ceftriaxone (as sodium) 2 g powder for injection
pfizer australia pty ltd - ceftriaxone sodium -
hospira ceftriaxone sodium powder for injection ceftriaxone (as sodium) 1 g powder for injection
pfizer australia pty ltd - ceftriaxone sodium -
hospira levetiracetam concentrate for iv infusion levetiracetam 500 mg/5 ml concentrate for infusion vial
pfizer australia pty ltd - levetiracetam, quantity: 500 mg - injection, concentrated - excipient ingredients: nitrogen; sodium acetate trihydrate; sodium chloride; glacial acetic acid; water for injections - hospira? levetiracetam concentrate for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible. levetiracetam is indicated for: use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation; monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy and add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy.